{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-25-033600","form_type":"8-K","ticker":"PHIO","cik":"0001533040","company_name":"Phio Pharmaceuticals Corp.","filed_at":"2025-11-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.664650+00:00","generated_at":"2026-05-16T23:39:51.985310+00:00","sec_items":["1.01","3.02","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Phio raises ~$13.4M via warrant exercise inducement; issues new warrants for 11.3M shares","bullets":["Entered inducement agreements for exercise of 5,663,182 existing warrants at reduced prices; gross proceeds ~$13.4M.","First closings Nov 4 & 6 generated ~$12.6M; second expected by Nov 18 for remaining 350,000 warrants.","Issued new unregistered Series A warrants to purchase up to 11,326,364 shares at $2.05, 24-month term.","Proceeds to fund working capital and accelerate development of PH-762 for cutaneous carcinomas.","H.C. Wainwright acting as placement agent; fees include 7.5% cash fee and placement agent warrants."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-25-033600","json":"https://secwatch.observer/filing/0001437749-25-033600.json","markdown":"https://secwatch.observer/filing/0001437749-25-033600.md","text":"https://secwatch.observer/filing/0001437749-25-033600.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1533040/000143774925033600/0001437749-25-033600-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1533040/000143774925033600/phio20251029_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T23:39:51.985310+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"208843ad72449ab61fecdfa86fcf449e389c4b9e","claim":"Phio Pharmaceuticals Corp. issued up to 424,739 shares of Common Stock of warrant to H.C. Wainwright & Co., LLC for services as placement agent.","evidence_excerpt":"Additionally, in connection with the above-mentioned offering, the Company agreed to issue to Wainwright or its designees as compensation, warrants to purchase up to an aggregate of 424,739 shares of Common Stock, equal to 7.5% of the aggregate number of Existing Warrants exercised in the offering (the “Placement Agent Warrants”) and, if the New Warrants are exercised for cash in the future, further warrants to purchase shares of Common Stock equal to the 7.5% of the aggregate number of New Warrants so exercised.","evidence_source":"SEC 8-K Item 3.02/3.03","evidence_url":"https://www.sec.gov/Archives/edgar/data/1533040/000143774925033600/0001437749-25-033600-index.htm","confidence":0.9,"family_label":"Equity Issuances","details":[{"label":"Security","value":"warrant"},{"label":"Shares","value":"up to 424,739 shares of Common Stock"},{"label":"Purchaser","value":"H.C. Wainwright & Co., LLC"},{"label":"Consideration","value":"services as placement agent"}],"fact_type":"equity_issuance"},{"claim_id":"9311e3b72f52a646133f7ad21fed761a8b27be2d","claim":"Phio Pharmaceuticals Corp. issued up to 11,326,364 shares of Common Stock of warrant to holders of existing common stock warrants for exercise of existing warrants for cash and payment of $0.125 per New Warrant, aggregate $1,415,795.50.","evidence_excerpt":"In consideration for the exercise of such warrants for cash and the payment of an additional $0.125 per New Warrant (as defined below), or an aggregate of $1,415,795.50 for all New Warrants, the Company agreed to issue to the Holders new unregistered Series A Warrants (the “New Warrants”) to purchase an aggregate of up to 11,326,364 shares of Common Stock (the “New Warrant Shares”).","evidence_source":"SEC 8-K Item 3.02/3.03","evidence_url":"https://www.sec.gov/Archives/edgar/data/1533040/000143774925033600/0001437749-25-033600-index.htm","confidence":0.95,"family_label":"Equity Issuances","details":[{"label":"Security","value":"warrant"},{"label":"Shares","value":"up to 11,326,364 shares of Common Stock"},{"label":"Purchaser","value":"holders of existing common stock warrants"},{"label":"Consideration","value":"exercise of existing warrants for cash and payment of $0.125 per New Warrant, aggregate $1,415,795.50"}],"fact_type":"equity_issuance"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}